Targets › FGF21
3 programs from 3 companies in 10 trials: 7 Phase 3, 2 Phase 2, 1 Phase 1; Gastroenterology, Metabolic and endocrine; next expected readout Dec 2026.
Stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression (but not SLC2A4/GLUT4 expression). Activity requires the presence of KLB. Regulates systemic glucose homeostasis and insulin sensitivity. (UniProt, Q9NSA1)
Open in Phaseline: the race on FGF21, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Efimosfermin alfa FGF21 analog | FGF21 | Phase 3 | Non-alcoholic Fatty Liver Disease; Metabolic Dysfunction-associated Steatohepatitis; Liver Diseases, Alcoholic | Oct 2027 |
| Akero Therapeutics | Efruxifermin FGF21 receptor agonist | FGF21 | Phase 3 | NASH/MASH; NASH - Nonalcoholic Steatohepatitis; NASH With Fibrosis | Feb 2030 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQA2225/AP025 FGF21-Fc fusion protein | FGF21 | Phase 2 | Non-alcoholic Steatohepatitis | Dec 2026 |
Non-alcoholic Fatty Liver Disease (3) Metabolic Dysfunction-associated Steatohepatitis (2) NASH/MASH (1) NASH - Nonalcoholic Steatohepatitis (1) NASH With Fibrosis (1) Liver Diseases, Alcoholic (1) Non-alcoholic Steatohepatitis (1)
protein or peptide (2)
Akero Therapeutics (1) GSK (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.